Vis enkel innførsel

dc.contributor.authorKleppe, Rune
dc.contributor.authorJonassen, Inge
dc.contributor.authorDoskeland, Stein Ove
dc.contributor.authorSelheim, Frode
dc.date.accessioned2019-07-30T12:11:40Z
dc.date.available2019-07-30T12:11:40Z
dc.date.issued2018-02-19
dc.PublishedKleppe R, Jonassen I, Doskeland SO, Selheim F. Mathematical modelling of nitric oxide/cyclic GMP/cyclic AMP signalling in platelets. International Journal of Molecular Sciences. 2018;19(2):612eng
dc.identifier.issn1422-0067en_US
dc.identifier.urihttps://hdl.handle.net/1956/20599
dc.description.abstractPlatelet activation contributes to normal haemostasis but also to pathologic conditions like stroke and cardiac infarction. Signalling by cGMP and cAMP inhibit platelet activation and are therefore attractive targets for thrombosis prevention. However, extensive cross-talk between the cGMP and cAMP signalling pathways in multiple tissues complicates the selective targeting of their activities. We have used mathematical modelling based on experimental data from the literature to quantify the steady state behaviour of nitric oxide (NO)/cGMP/cAMP signalling in platelets. The analysis provides an assessment of NO-induced cGMP synthesis and PKG activation as well as cGMP-mediated cAMP and PKA activation though modulation of phosphodiesterase (PDE2 and 3) activities. Both one- and two-compartment models of platelet cyclic nucleotide signalling are presented. The models provide new insight for understanding how NO signalling to cGMP and indirectly cAMP, can inhibit platelet shape-change, the initial step of platelet activation. Only the two-compartment models could account for the experimental observation that NO-mediated PKA activation can occur when the bulk platelet cAMP level is unchanged. The models revealed also a potential for hierarchical interplay between the different platelet phosphodiesterases. Specifically, the models predict, unexpectedly, a strong effect of pharmacological inhibitors of cGMP-specific PDE5 on the cGMP/cAMP cross-talk. This may explain the successful use of weak PDE5-inhibitors, such as dipyridamole, in anti-platelet therapy. In conclusion, increased NO signalling or PDE5 inhibition are attractive ways of increasing cGMP-cAMP cross-talk selectively in platelets.en_US
dc.language.isoengeng
dc.publisherMDPIen_US
dc.rightsAttribution CC BYeng
dc.rights.urihttp://creativecommons.org/licenses/by/4.0eng
dc.subjectnitric oxideeng
dc.subjectplateletseng
dc.subjectcGMP signallingeng
dc.subjectcAMP signallingeng
dc.subjectmathematical modellingeng
dc.subjectphosphodiesteraseeng
dc.subjectPDE2eng
dc.subjectPDE3eng
dc.subjectPDE5eng
dc.titleMathematical modelling of nitric oxide/cyclic GMP/cyclic AMP signalling in plateletsen_US
dc.typePeer reviewed
dc.typeJournal article
dc.date.updated2019-01-26T13:11:24Z
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2018 The Author(s)en_US
dc.identifier.doihttps://doi.org/10.3390/ijms19020612
dc.identifier.cristin1638051
dc.source.journalInternational Journal of Molecular Sciences


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution CC BY
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution CC BY